Last week, the Department of Health and Human Services welcomed its third group of “entrepreneurs-in-residence” — mainly private-sector tech experts and start-up founders who are spending a year advising the agency on its health IT projects.
AstraZeneca became the latest biotechnology company to expand its manufacturing operations in Maryland when the British drugmaker announced plans last month to enlarge a production facility and add 300 workers in Frederick.
Pieris AG has achieved the fourth milestone payment for its lead Anticalin® program with Daiichi Sankyo Company, Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the sixth milestone achieved for the parties’ two R&D collaborative projects. Specifically, the milestone was the decision by Daiichi Sankyo to initiate a GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which is responsible for further development of the program.
Takeda Pharmaceutical Company Limited (TSE:4502) today announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology research and development while expanding its global commercial network and resources as Takeda Oncology. Takeda is retiring the Millennium: The Takeda Oncology Company brand, and replacing it with Takeda Oncology to reflect the new global oncology business unit.
Blueprint Health has formed an interdisciplinary group inside and outside of healthcare to develop and assess new healthcare technologies earlier in an effort to reduce risk and to better predict the ROI of solutions earlier, according to a company statement. The Blueprint Health Collective will be totally separate from its New York City-based accelerator.
Steve Silverman resigned this week as the director of the Montgomery County Department of Economic Development.
County spokesman Patrick Lacefield said Silverman, who has served in the role since 2009, left the post to purse a job in the private sector.
Governor Terry McAuliffe on Thursday announced a Virginia Bioscience Initiative, kicking off the effort with a public and private sector roundtable discussion on the commercialization of university bioscience research at the State Capitol. University representatives and bio industry leaders joined the Governor, members of his administration and renowned Massachusetts Institute of Technology Professor Dr. Robert S. Langer for this discussion.
Canadian researchers have developed “smart textiles” able to monitor and transmit wearers’ biomedical information via wireless or cellular network by superimposing multiple layers of copper, polymers, glass, and silver.
GI View out of Ramat Gan, Israel finally won FDA clearance to introduce to the U.S. market its self-propelled single-use Aer-O-Scope colonoscope. This device originally appeared on our radar almost a decade ago, but the regulatory road seems to have been rocky for GI View, and the company expects it will be at least another year before it begins introducing the Aer-O-Scope to the U.S. market.
I was asked by the U.S.-UK Fulbright Commission to give a series of lectures in the United Kingdom in 2013 on the topic of diplomacy. This was surprising, as I am even marginally competent in only one domain of diplomacy—the forms of international relations that involve nations working together in fields of medical science and health. So I proposed to address the question of what accounted for the success—despite inherent difficulties and adverse circumstances—of three important and ambitious international initiatives in medicine and related science undertaken by the United States.